

## Commercial Recruitment to Target

Research Ethics Committee		Recruitment Target	Recruitment End Date	Study Status	Performance Against Target
Reference	Study Title				
11/WA/0363	A Phase 2 MultiCenter, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)	1	31/03/2014	Closed - Follow Up Complete	Target Not Met
13/NE/0049	MCRN224 (BAY 94-9027)	1	30/04/2014	Closed - In Follow Up	Target Met
11/SC/0327	CCRN 601 (Crohn's Disease)	5	30/06/2014	Closed - Follow Up Complete	Target Not Met
12/NW/0585	Trastuzumab Emtansine (TDM1) (GATSBY)	2	31/07/2014	Closed - In Follow Up	Target Met
13/YH/022	MCRN221 MCI-196-E16	2	31/07/2014	Withdrawn	Withdrawn
13/EM/0254	PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	3	31/08/2014	Closed - In Follow Up	Target Met
GTAC185	PROSTVAC - Efficacy study of PROSTVAC vaccine in patients with prostate cancer	5	31/08/2014	Closed - In Follow Up	Target Met
14/EM/0001	TREND (CRFB002A2411)	5	05/09/2014	Closed - In Follow Up	Target Met
10/H0406/45	ABBOTT 877 CCRN 281 (Active uveitis)	4	16/09/2014	Closed - Follow Up Complete	Target Met
13/SC/0213	ACT IV Study - Protocol CDX110-04	6	30/09/2014	Closed - In Follow Up	Target Not Met
13/NW/0464	CCRN 2274 (Liver failure)	4	30/09/2014	Closed - Follow Up Complete	Target Not Met
13/EE/0377	M12-813: Elagolix in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids	4	30/09/2014	Closed - In Follow Up	Target Not Met
14/NE/0122	WA29231- LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS	1	30/09/2017	Open	Still open to Recruitment
13/NE/0294	ROCHE PHASE I SINGLE ASCENDING DOSE Study of RO6867461 in wAMD	3	30/12/2014	Closed - Follow Up Complete	Target Met
10/H0406/46	ABBOTT 880 CCRN 282 (Inactive uveitis)	4	31/12/2014	Closed - Follow Up Complete	Target Met
12/LO/0080	OCTAVE A3921095: 007: Oral CP690,550 as an Induction Therapy for Ulcerative Colitis	5	31/12/2014	Open	Still open to Recruitment
12/LO/0082	OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of Ulcerative Colitis	5	31/05/2015	Open	Still open to Recruitment
13/YH/0021	MCRN223 MCI-196-E15 Extension Study Evaluating Colestilan	2	31/12/2014	Withdrawn	Withdrawn
12/WA/1064	ZEST	4	31/12/2014	Closed - Follow Up Complete	Target Met
13/EE/0263	MASTER II Trial	20	31/12/2014	Closed - In Follow Up	Target Met
12/EE/0071	CCRN 923 (Ascites)	6	31/12/2014	Closed - In Follow Up	Target Met
13/NW/0002	CCRN 1073 (Thoracic aortic surgery)	15	31/12/2014	Closed - Follow Up Complete	Target Met
12/SC/0309	NCRN371 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia	1	31/01/2015	Closed - In Follow Up	Target Met
10/H1003/120	Intravenous zanamivir versus oral oseltamivir in hospitalised influenza (NAI114373 - ZORO)	2	27/02/2015	Closed - Follow Up Complete	Target Not Met
13/WA/0269	CCRN 771 (Endometriosis-related pain)	6	28/02/2015	Withdrawn	Withdrawn
13/YH/0020	MCRN222 (MCI-196-E14)	1	28/02/2015	Withdrawn	Withdrawn
14/SC/0100	JETREA FIRSTLINE (ALCON) - Assessment of Patients Treated With JETREA® for Vitreomacular Traction	5	06/03/2015	Withdrawn	Withdrawn
13/YH/0136	CCRN 2173 (AI Liver Decompensation)	2	30/03/2015	Closed - In Follow Up	Target Not Met
13/NW/0320	MCRN235 (WA28117)	2	31/03/2015	Closed - In Follow Up	Target Met
13/LO/0720	NCRN492 - NEMO-MEK162 vs Dacarbazine in NRAS mutation positive melanoma patients	2	31/03/2015	Closed - In Follow Up	Target Not Met
14/NW/0008	GO-COLITIS	6	31/03/2015	Withdrawn	Withdrawn
14/EE/1001	OTO-104 in Meniere's Disease	5	17/04/2015	Open	Still open to Recruitment
12/LO/0081	OCTAVE A3921096: 008: Oral CP-690, 550 as Maintenance Therapy for Ulcerative Colitis	3	30/04/2015	Open	Still open to Recruitment
14/SW/0079	CCRN - 3308 The DEFLECT III Trial	6	30/04/2015	Open	Still open to Recruitment
14/YH/0048	Apposition V	25	30/04/2015	Withdrawn	Withdrawn

## Commercial Recruitment to Target

Research Ethics Committee Reference		Study Title	Recruitment Target	Recruitment End Date	Study Status	Performance Against Target
10/H1308/84		NCRN252 - Nilotinib in paediatric Ph+ CML/ALL	1	31/05/2015	Open	Still open to Recruitment
12/SC/0434		(MCRN194) DPM-CF-204 mannitol in CF aged 6-17	4	31/05/2015	Open	Still open to Recruitment
13/YH/0126		GWCA1208 - Study of Sativex in Patients with Recurrent Glioblastoma	4	31/05/2015	Open	Still open to Recruitment
13/EE/0367		CCRN 2215 (Crohn's)	3	31/05/2015	Open	Still open to Recruitment
14/WM/1228		CHIL3846 Abbott Sensor Based Glucose Monitoring System Paediatric Study (BEAGLE)	13	31/05/2015	Open	Still open to Recruitment
12/LO/1090		NCRN: 416 MetMAB - YO28322	4	01/06/2015	Closed - In Follow Up	Target Met
12/NW/0641		NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma	9	15/06/2015	Open	Still open to Recruitment
13/ES/0005		NCRN525 (AZACITIDINE + BSC v PLACEBO + BSC)	2	30/06/2015	Open	Still open to Recruitment
13/LO/0716		CCRN 2159 (Uveitis)	4	30/06/2015	Open	Still open to Recruitment
13/LO/0945		MCRN 2419: KOGNITO (Kuvan®'s effect on the cOGNITion of children with phenylketonuria)	2	31/07/2015	Open	Still open to Recruitment
13/SC/0007		An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Unresectable Melanoma.	5	31/07/2015	Open	Still open to Recruitment
13/SC/0268		CCRN2100 (Cystic fibrosis)	5	31/07/2015	Open	Still open to Recruitment
13/LO/0150		NCRN561 : The regorafenib in patients with hepatocellular carcinoma (RESORCE)	2	01/08/2015	Open	Still open to Recruitment
13/SW/0186		EFFECT - Efficacy of Fluticasone/Formoterol in COPD Treatment	4	31/08/2015	Withdrawn	Withdrawn
13/EM/0149		15961 GadaCAD1	15	31/08/2015	Withdrawn	Withdrawn
14/SC/1014		CANC - 3482 JANUS 1: Ruxolitinib or placebo + Capecitabine in pancreatic adenocarcinoma	2	30/09/2015	Open	Still open to Recruitment
14/YH/1124		EXTEND (2819MA1002)	3	30/09/2015	Open	Still open to Recruitment
13/LO/0161		MAESTRO: Macitentan in Eisenmenger Syndrome AC-055-305 (CCRN 2104)	3	01/10/2015	Open	Still open to Recruitment
13/LO/1283		MO 28037 - TAMIGA	6	30/10/2015	Closed - In Follow Up	Target Met
12/NW/0367		MCRN177 (BEL114055)	1	31/10/2015	Open	Still open to Recruitment
13/LO/0717		CL3-78989-006. EYEGUARD-C study	4	30/11/2015	Open	Still open to Recruitment
14/EM/0034		NCRN3025 - GDC-0199 in CLL (GO28667) - MURANO	2	30/11/2015	Open	Still open to Recruitment
14/EM/0130		NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy	2	01/12/2015	Open	Still open to Recruitment
13/WS/0304		EVARREST (The Fibrin Pad CV Phase III Study)	10	31/12/2015	Open	Still open to Recruitment
13/YH/0201		MCRN2280 Sativex Severe Spasticity (GWSP08258)	6	31/12/2015	Open	Still open to Recruitment
13/LO/1608		Study of efficacy and safety of nilotinib in paediatric CML patients	1	31/12/2015	Open	Still open to Recruitment
14/LO/0036		NCRN2555 - TOWER Study (00103311)	5	31/01/2016	Open	Still open to Recruitment
13/SC/0171		Study of Moxetumomab Pasudotox in pALL or LL of B-Cell	1	31/01/2016	Open	Still open to Recruitment
14/EM/0215		M12-914 Phase III Veliparib/Placebo + C/P Breast Cancer Study	1	29/02/2016	Open	Still open to Recruitment
10/H0406/47		ABBOTT 327 CCRN 283 (LT uveitis)	8	31/03/2016	Open	Still open to Recruitment
14/NI/1075		CHIL3670 (ALX0171-C104)	1	31/03/2016	Open	Still open to Recruitment
12/SW/0084		LFG316 MFC	5	01/04/2016	Suspended	Still open to Recruitment
13/LO/0520		OCTAVE, Ranibizumab in neovascular age-related macular degeneration(CRFB002A2405)	4	16/04/2016	Closed - In Follow Up	Target Met

## Commercial Recruitment to Target

Research Ethics Committee		Recruitment Target	Recruitment End Date	Study Status	Performance Against Target
Reference	Study Title				
13/WA/0101	CCRN 2088 (Pneumonia)	6	30/04/2016	Open	Still open to Recruitment
14/YH/0007	MCRN2368 UCB PRA Epilepsy Lacosamide SP0969	2	24/05/2016	Open	Still open to Recruitment
14/NW/0001	Continuation Study of Prophylactic BAX 855 in PTP with Haemophilia A	2	31/05/2016	Closed - In Follow Up	Target Met
14/EE/1063	AZD9291 v chemotherapy in NSCLC, following EGFR TKI therapy (AURA3)	3	31/05/2016	Open	Still open to Recruitment
14/WS/0004	Odyssey OLE	10	03/06/2016	Open	Still open to Recruitment
13/EM/0012	NCRN490: CA184-178 Ipilimumab in children(aged 12<18)with malignant melanoma	1	30/06/2016	Open	Still open to Recruitment
14/LO/1617	DRN3544 - GLP110933 study Type I DM Study	2	14/08/2016	Open	Still open to Recruitment
13/NW/0705	COAST BAY73-4506/15983: Regorafenib as adjuvant therapy for resected liver metastases	7	31/08/2016	Open	Still open to Recruitment
14/SC/1425	CCRN 2738 (AMD)	7	31/10/2016	Open	Still open to Recruitment
15/NW/0009	MCRN3127 (20130173)	3	28/02/2017	Open	Still open to Recruitment
14/WM/0013	MCRN2947 (ALS-8176-503) Developing a new drug to treat infants hospitalised with RSV infection	8	30/04/2017	Open	Still open to Recruitment
11/LO/0923	NCRN259 HERBY - Bevacizumab in paediatric high grade glioma	3	22/08/2017	Closed - In Follow Up	Target Met
11/SC/0329	CCRN 602 (Crohn's disease)	5	31/10/2017	Closed - In Follow Up	Target Not Met
13/LO/0418	SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	2	31/10/2017	Open	Still open to Recruitment
14/NE/1099	GA29103: PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS	1	31/12/2017	Open	Still open to Recruitment